Free Trial
→ A little-known law has been quietly applied to your savings for years. (From Monetary Gold) (Ad)tc pixel Free OTLK Stock Alerts

Oncobiologics (OTLK) Financials

Oncobiologics logo
$0.42 -0.02 (-5.25%)
As of 12:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Oncobiologics

Annual Income Statements for Oncobiologics

This table shows Oncobiologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 -53 -63 -40 -48 -36 -49 -53 -66 -59 -75
Consolidated Net Income / (Loss)		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Net Income / (Loss) Continuing Operations		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Total Pre-Tax Income 		-49 -53 -38 -34 -38 -39 -53 -66 -59 -75
Total Operating Income		 -47 -51 -36 -30 -36 -37 -52 -63 -53 -72
Total Gross Profit		 5.22 2.98 3.81 3.09 8.15 0.00 0.00 0.00 0.00 0.00
Total Revenue		 5.22 2.98 3.81 3.09 8.15 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 52 54 40 33 44 37 52 63 53 72
Selling, General & Admin Expense		 13 22 16 14 9.37 9.97 13 21 27 30
Research & Development Expense		 39 33 24 19 24 26 39 42 26 42
Total Other Income / (Expense), net		 -2.30 -1.85 -2.47 -4.10 -1.64 -1.67 -1.43 -2.98 -5.85 -3.66
Interest Expense		 2.30 1.85 5.63 5.14 4.07 3.65 0.94 2.51 3.11 41
Interest & Investment Income		 - - - - - 0.00 -0.05 -0.05 0.96 0.81
Other Income / (Expense), net		 - - 3.16 1.05 2.44 1.98 -0.45 -0.42 -3.71 36
Income Tax Expense		 -0.19 0.10 0.50 -3.65 -3.41 -3.27 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($5.43) ($3.67) ($1.67) ($9.74) ($1.98) ($0.67) ($0.35) ($0.31) ($4.72) ($4.06)
Weighted Average Basic Shares Outstanding		 9.75M 17.21M 24.02M 4.93M 18.19M 72.56M 152.68M 212.08M 12.51M 18.55M
Diluted Earnings per Share		 ($5.43) ($3.67) ($1.80) ($9.74) ($1.98) ($0.67) ($0.35) ($0.31) ($4.72) ($4.06)
Weighted Average Diluted Shares Outstanding		 9.75M 17.21M 24.04M 4.93M 18.19M 72.56M 152.68M 212.08M 12.51M 18.55M
Weighted Average Basic & Diluted Shares Outstanding		 9.75M 17.21M 25.53M 4.93M 18.19M 72.56M 224.26M 228.21M 260.26M 24.91M

Quarterly Income Statements for Oncobiologics

This table shows Oncobiologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45 -20
Consolidated Net Income / (Loss)		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45 -20
Net Income / (Loss) Continuing Operations		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45 -20
Total Pre-Tax Income 		-13 0.00 -114 44 5.69 17 -46 -20 -23 -4.45 -20
Total Operating Income		 -12 -10 -19 -20 -23 -22 -12 -16 -13 -14 -11
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 1.07 -1.24 -0.02 -0.01
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 1.51 -1.21 0.13 0.01
Operating Revenue		 - - - 0.00 - 0.00 0.00 1.51 -1.21 0.13 0.01
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.44 0.03 0.15 0.02
Operating Cost of Revenue		 - - - 0.00 - 0.00 0.00 0.44 0.03 0.15 0.02
Total Operating Expenses		 12 10 19 20 23 22 12 17 12 14 11
Selling, General & Admin Expense		 7.51 5.79 5.43 8.36 10 12 7.98 9.68 8.61 9.50 7.55
Research & Development Expense		 4.94 4.53 14 11 13 9.66 4.41 7.13 3.63 4.50 3.25
Total Other Income / (Expense), net		 -0.53 -0.86 -95 64 29 39 -34 -4.40 -9.57 9.57 -9.51
Interest Expense		 0.27 -0.19 37 -0.40 0.26 -0.05 0.02 0.05 0.00 -0.29 1.33
Interest & Investment Income		 0.57 0.00 -0.03 -0.06 0.49 - -0.04 -0.03 -0.04 -0.05 -0.04
Other Income / (Expense), net		 -0.83 -1.05 -58 64 28 39 -34 -4.32 -9.54 9.33 -8.14
Income Tax Expense		 - - 0.00 0.00 - - 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($1.04) ($0.86) ($8.01) $1.91 $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05) ($0.15)
Weighted Average Basic Shares Outstanding		 12.51M 13.01M 14.27M 23.23M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M 136.74M
Diluted Earnings per Share		 ($1.04) ($0.86) ($8.01) ($0.89) $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05) ($0.15)
Weighted Average Diluted Shares Outstanding		 12.51M 13.01M 14.27M 25.48M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M 136.74M
Weighted Average Basic & Diluted Shares Outstanding		 260.26M 260.26M 23.41M 23.66M 24.91M 32.02M 33.57M 44.42M 83.07M 120.86M 243.45M

Annual Cash Flow Statements for Oncobiologics

This table details how cash moves in and out of Oncobiologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Net Change in Cash & Equivalents		 6.72 -6.72 0.83 -1.47 6.30 4.52 1.94 2.92 6.00 -8.46
Net Cash From Operating Activities		 -27 -45 -16 -33 -32 -32 -54 -57 -43 -69
Net Cash From Continuing Operating Activities		 -27 -45 -16 -33 -32 -32 -54 -57 -43 -69
Net Income / (Loss) Continuing Operations		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Consolidated Net Income / (Loss)		 -49 -53 -39 -30 -35 -35 -53 -66 -59 -75
Depreciation Expense		 1.82 2.39 2.69 3.05 3.36 0.55 0.26 0.20 0.04 0.11
Non-Cash Adjustments To Reconcile Net Income		 11 12 9.49 7.68 12 4.00 5.58 11 11 9.48
Changes in Operating Assets and Liabilities, net		 8.18 -7.05 11 -14 -13 -1.11 -6.93 -1.64 4.78 -3.02
Net Cash From Investing Activities		 -8.80 -1.10 -0.29 -2.78 -0.44 -0.90 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 -8.80 -1.10 -0.29 -2.78 -0.44 -0.90 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 43 40 17 34 39 37 56 60 49 60
Net Cash From Continuing Financing Activities		 43 40 17 34 39 37 56 60 49 60
Repayment of Debt		 -9.30 -14 -3.71 -2.08 -6.42 -0.05 -3.67 -13 -11 0.00
Issuance of Debt		 11 1.03 15 - 0.00 0.90 10 10 30 0.00
Issuance of Common Equity		 42 53 1.61 15 46 35 46 62 30 60
Other Financing Activities, net		 -0.00 3.81 0.25 - -0.52 0.92 3.56 0.18 -0.01 -0.00
Cash Interest Paid		 1.40 2.06 1.34 0.11 2.79 0.91 0.05 1.56 1.16 0.48

Quarterly Cash Flow Statements for Oncobiologics

This table details how cash moves in and out of Oncobiologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -10 -13 37 -15 -17 -9.22 1.85 1.34 0.59 -0.93 3.49
Net Cash From Operating Activities		 -13 -13 -19 -20 -17 -11 -17 -12 -15 -7.83 -21
Net Cash From Continuing Operating Activities		 -13 -13 -19 -20 -17 -11 -17 -12 -15 -7.83 -21
Net Income / (Loss) Continuing Operations		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45 -20
Consolidated Net Income / (Loss)		 -13 -11 -114 44 5.69 17 -46 -20 -23 -4.45 -20
Depreciation Expense		 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.01
Non-Cash Adjustments To Reconcile Net Income		 2.23 2.32 96 -62 -27 -35 36 6.04 10 -8.82 10
Changes in Operating Assets and Liabilities, net		 -1.99 -4.20 -1.26 -1.78 4.22 6.90 -5.91 2.19 -2.37 5.41 -11
Net Cash From Investing Activities		 - 0.00 - - - 0.00 - - 0.00 - -2.10
Net Cash From Continuing Investing Activities		 - 0.00 - - - 0.00 - - 0.00 - -2.10
Net Cash From Financing Activities		 2.42 -0.00 56 4.31 -0.11 1.74 18 13 16 6.90 27
Net Cash From Continuing Financing Activities		 2.42 -0.00 56 4.31 -0.11 1.74 18 13 16 6.90 27
Repayment of Debt		 - - - - - - - -0.91 - - 16
Issuance of Debt		 - 0.00 - - - - - - - - -17
Issuance of Common Equity		 2.43 0.00 56 4.31 -0.11 1.74 1.42 14 15 6.90 25
Other Financing Activities, net		 -0.00 -0.00 -0.00 - - 0.00 17 - 0.60 - 4.32

Annual Balance Sheets for Oncobiologics

This table presents Oncobiologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 35 25 21 22 17 20 23 29 32 29 19
Total Current Assets		 15 5.68 3.90 3.30 14 18 22 28 31 27 17
Cash & Equivalents		 9.07 2.35 3.19 1.72 8.02 13 14 17 23 15 8.08
Accounts Receivable		 0.02 - - - - - - - - 0.00 1.49
Inventories, net		 - - - - - - - - - 0.00 3.34
Prepaid Expenses		 1.79 3.33 0.72 1.59 4.99 5.41 7.03 10 7.59 12 4.48
Plant, Property, & Equipment, net		 18 19 16 18 3.18 0.33 0.16 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 2.08 1.07 0.74 0.49 0.46 1.46 1.14 1.01 1.32 1.41 1.20
Long-Term Investments		 - - - - - 0.00 0.85 0.80 0.79 0.69 0.55
Other Noncurrent Operating Assets		 1.87 0.85 0.74 0.49 0.46 1.46 0.29 0.20 0.53 0.71 0.64
Total Liabilities & Shareholders' Equity		 35 25 21 22 17 20 23 29 32 29 19
Total Liabilities		 63 31 51 43 28 17 18 20 47 102 51
Total Current Liabilities		 37 20 29 32 20 16 6.75 20 47 43 46
Short-Term Debt		 16 6.18 5.01 14 11 3.66 0.90 11 36 29 30
Accounts Payable		 12 5.07 11 3.61 2.28 2.39 2.20 3.49 6.57 7.97 10
Accrued Expenses		 5.92 6.12 7.34 6.46 4.62 7.76 1.73 3.43 2.75 3.24 5.31
Current Deferred & Payable Income Tax Liabilities		 1.75 1.85 2.35 1.86 1.86 1.86 1.86 1.86 1.86 1.86 0.30
Other Current Liabilities		 - - - 4.61 0.19 0.22 0.07 0.04 0.00 0.05 0.06
Total Noncurrent Liabilities		 26 10 23 11 7.61 1.02 11 0.06 0.01 59 4.96
Long-Term Debt		 4.92 2.23 13 0.10 0.05 0.90 11 - - 0.00 0.00
Other Noncurrent Operating Liabilities		 0.28 2.43 4.84 4.74 7.56 0.11 0.57 0.06 0.01 59 4.96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -55 -5.17 -34 -26 -16 2.83 4.61 8.74 -14 -73 -32
Total Preferred & Common Equity		 -54 -5.17 -34 -26 -16 2.83 4.61 8.74 -14 -73 -32
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -54 -5.17 -34 -26 -16 2.83 4.61 8.74 -14 -73 -32
Common Stock		 40 142 153 191 238 293 347 418 453 470 574
Retained Earnings		 -94 -147 -186 -216 -254 -290 -343 -409 -468 -543 -606

Quarterly Balance Sheets for Oncobiologics

This table presents Oncobiologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Assets		 22 59 47 17 19 22 18 22 26
Total Current Assets		 20 58 46 16 18 21 17 21 23
Cash & Equivalents		 10 47 32 5.70 7.56 8.90 8.68 7.75 11
Accounts Receivable		 - - - - - 1.75 0.11 2.72 1.64
Inventories, net		 - - - 3.11 3.60 4.13 3.46 3.34 5.04
Prepaid Expenses		 10 11 14 6.86 6.65 6.32 4.92 7.09 5.24
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.30 1.24 1.47 1.34 1.27 1.30 1.07 0.99 3.02
Long-Term Investments		 0.80 0.77 0.71 0.66 0.62 0.59 0.51 0.47 2.53
Other Noncurrent Operating Assets		 0.50 0.48 0.77 0.68 0.64 0.70 0.56 0.52 0.49
Total Liabilities & Shareholders' Equity		 22 59 47 17 19 22 18 22 26
Total Liabilities		 46 193 131 67 52 60 57 51 37
Total Current Liabilities		 46 54 43 48 25 31 49 39 29
Short-Term Debt		 37 45 32 31 12 14 37 16 0.00
Accounts Payable		 3.48 4.36 5.55 12 7.77 10 7.32 14 6.81
Accrued Expenses		 4.09 3.12 2.68 3.39 3.15 5.31 4.71 9.04 3.28
Current Deferred & Payable Income Tax Liabilities		 1.86 1.86 1.86 1.86 1.86 1.86 0.30 0.30 0.30
Other Current Liabilities		 0.00 0.00 0.03 0.05 0.05 0.06 0.06 0.06 18
Total Noncurrent Liabilities		 0.06 139 88 19 27 28 7.73 12 7.90
Long-Term Debt		 - - - - 21 20 - 11 0.00
Other Noncurrent Operating Liabilities		 0.06 139 88 19 5.67 7.66 7.73 0.88 7.90
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -24 -134 -84 -50 -32 -37 -39 -29 -10
Total Preferred & Common Equity		 -24 -134 -84 -50 -32 -37 -39 -29 -10
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -24 -134 -84 -50 -32 -37 -39 -29 -10
Common Stock		 455 459 465 476 540 555 590 604 643
Retained Earnings		 -479 -593 -549 -526 -572 -592 -629 -633 -654

Annual Metrics And Ratios for Oncobiologics

This table displays calculated financial ratios and metrics derived from Oncobiologics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -42.91% 27.92% -18.99% 163.84% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -9.42% 38.66% 14.94% -19.41% -12.48% -51.34% -21.89% 10.26% 37.65%
EBIT Growth		 0.00% -10.28% 36.27% 12.61% -18.41% -2.95% -49.69% -21.67% 10.48% 37.50%
NOPAT Growth		 0.00% -10.28% 30.12% 17.38% -22.45% -1.49% -40.41% -21.93% 15.77% -34.97%
Net Income Growth		 0.00% -9.52% 27.12% 22.54% -14.73% -2.07% -50.86% -24.24% 10.70% -27.78%
EPS Growth		 0.00% 32.41% 50.95% 22.54% 79.67% 66.16% 47.76% 11.43% 10.70% 13.98%
Operating Cash Flow Growth		 0.00% -65.53% 65.91% -113.09% 2.27% 1.55% -70.66% -4.46% 24.18% -60.08%
Free Cash Flow Firm Growth		 0.00% 0.00% 83.34% -259.58% 25.18% -20.77% -51.26% -4.99% 26.65% 118.34%
Invested Capital Growth		 0.00% 106.65% -1,665.36% 66.38% -42.00% 30.48% 120.74% 35.94% -311.93% -1,828.51%
Revenue Q/Q Growth		 0.00% 0.00% 171.42% -40.83% 165.82% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 25.48% -43.23% -2.91% 5.01% -7.56% -0.72% 1.13% 34.65%
EBIT Q/Q Growth		 0.00% 0.00% 23.76% -37.93% -2.82% 6.98% -7.46% -0.72% 1.20% 34.55%
NOPAT Q/Q Growth		 0.00% 0.00% 16.41% -47.18% -0.77% 6.78% -7.08% -0.88% 2.80% -17.00%
Net Income Q/Q Growth		 0.00% 0.00% 9.75% -24.01% 5.74% 0.49% -7.01% -1.44% 2.24% 19.86%
EPS Q/Q Growth		 0.00% 0.00% -2.27% -24.01% -18.56% -24.07% -20.69% -3.33% 2.24% -0.25%
Operating Cash Flow Q/Q Growth		 0.00% 1.39% 40.26% -34.50% 7.06% -23.92% 5.38% -2.27% -6.15% -6.57%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -15.01% 3.30% -42.61% 8.51% -2.78% -11.60% -83.26%
Invested Capital Q/Q Growth		 0.00% 0.00% -28.10% -758.87% -1,705.97% 38.84% -74.25% -60.90% 41.82% 29.43%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -857.18% -1,642.95% -787.87% -827.26% -374.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -892.13% -1,723.30% -941.36% -960.12% -445.60% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -892.13% -1,723.30% -858.50% -926.19% -415.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -932.51% -1,788.91% -1,019.26% -974.62% -423.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.61% 100.19% 101.31% 89.19% 91.01% 91.50% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.93% 103.61% 117.19% 117.99% 112.03% 110.48% 101.88% 104.03% 103.78% 212.16%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 176.64% 325.75% 216.43% 116.78% 218.64% 887.24% -1,430.33% -989.99% 2,069.13% 172.24%
Cash Return on Invested Capital (CROIC)		 0.00% -5,233.87% 0.00% 0.00% 0.00% 0.00% -3,977.23% -3,539.46% 0.00% 0.00%
Operating Return on Assets (OROA)		 -133.00% -169.98% -141.84% -132.95% -171.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -139.02% -176.45% -168.40% -139.91% -175.17% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 347.61% 591.20% 234.06% 134.13% 288.52% 1,485.83% -1,430.33% -989.99% 2,069.13% 172.24%
Return on Equity Simple (ROE_SIMPLE)		 89.76% 1,030.41% 115.45% 117.80% 214.04% -1,246.85% -1,153.86% -756.04% 408.53% 103.13%
Net Operating Profit after Tax (NOPAT)		 -33 -36 -25 -21 -25 -26 -36 -44 -37 -50
NOPAT Margin		 -624.49% -1,206.31% -658.95% -672.08% -311.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 126.81% 184.28% 128.38% 60.59% 96.08% -411.22% -294.61% -404.57% 1,068.77% 199.92%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -176.14% 115.02%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 247.27% 723.71% 416.69% 460.81% 115.02% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 744.86% 1,099.59% 624.68% 599.31% 292.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 992.13% 1,823.30% 1,041.36% 1,060.12% 545.60% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -47 -51 -33 -29 -34 -35 -52 -63 -57 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -49 -30 -26 -30 -34 -52 -63 -57 -35
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 32.40 82.58 31.58 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 32.40 82.58 31.58 0.00 0.00
Price to Revenue (P/Rev)		 0.00 32.53 8.87 22.92 5.16 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 104.35 0.00 0.00 0.00 0.00 353.44 185.27 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 34.67 13.63 29.50 6.24 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 23.39
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 -0.80 -1.69 -0.60 -0.83 -1.06 1.62 2.56 1.25 -2.46 -0.40
Long-Term Debt to Equity		 -0.22 -0.49 -0.44 -0.17 0.00 0.32 2.36 0.00 0.00 0.00
Financial Leverage		 -0.46 -0.58 -0.60 -0.60 -0.60 0.58 -1.55 -0.81 -0.72 -0.29
Leverage Ratio		 -1.27 -1.85 -1.29 -0.83 -1.25 -4.64 5.72 3.85 -10.67 -0.70
Compound Leverage Factor		 -1.33 -1.91 -1.51 -0.98 -1.40 -5.13 5.83 4.00 -11.07 -1.48
Debt to Total Capital		 -392.83% 245.39% -149.62% -495.94% 1,842.72% 61.77% 71.90% 55.54% 168.38% -67.47%
Short-Term Debt to Total Capital		 -282.97% 173.59% -40.67% -394.23% 1,834.59% 49.54% 5.51% 55.54% 168.38% -67.47%
Long-Term Debt to Total Capital		 -109.86% 71.80% -108.95% -101.71% 8.14% 12.23% 66.39% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -476.99% 0.00% -23.76% -135.58% 867.22% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 969.82% -145.39% 273.38% 731.52% -2,609.95% 38.23% 28.10% 44.46% -68.38% 167.47%
Debt to EBITDA		 -0.49 -0.18 -0.61 -0.68 -0.37 -0.13 -0.23 -0.17 -0.63 -0.83
Net Debt to EBITDA		 -0.29 -0.13 -0.51 -0.61 -0.11 0.23 0.07 0.12 -0.20 -0.39
Long-Term Debt to EBITDA		 -0.14 -0.05 -0.45 -0.14 0.00 -0.03 -0.21 0.00 0.00 0.00
Debt to NOPAT		 -0.67 -0.24 -0.73 -0.83 -0.45 -0.18 -0.33 -0.25 -0.96 -0.59
Net Debt to NOPAT		 -0.40 -0.18 -0.61 -0.75 -0.13 0.31 0.10 0.17 -0.31 -0.28
Long-Term Debt to NOPAT		 -0.19 -0.07 -0.53 -0.17 0.00 -0.04 -0.30 0.00 0.00 0.00
Altman Z-Score		 0.00 -13.47 -18.64 -18.25 -26.41 -23.01 -15.28 -18.72 -25.93 -30.34
Noncontrolling Interest Sharing Ratio		 -96.79% -81.49% -8.15% -14.86% -31.96% -67.47% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.41 0.28 0.14 0.10 0.67 1.13 3.19 1.39 0.66 0.64
Quick Ratio		 0.25 0.12 0.11 0.05 0.40 0.79 2.14 0.88 0.50 0.35
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -52 -8.63 -31 -23 -28 -42 -45 -33 5.99
Operating Cash Flow to CapEx		 -312.08% -4,141.64% -5,308.39% -1,187.99% -7,383.83% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -27.98 -1.53 -6.03 -5.70 -7.68 -45.31 -17.72 -10.51 0.15
Operating Cash Flow to Interest Expense		 -11.96 -24.56 -2.76 -6.42 -7.93 -8.70 -57.96 -22.55 -13.82 -1.69
Operating Cash Flow Less CapEx to Interest Expense		 -15.79 -25.15 -2.81 -6.96 -8.03 -8.70 -57.96 -22.55 -13.82 -1.69
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.15 0.10 0.17 0.14 0.41 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 260.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.29 0.16 0.22 0.18 0.75 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 1.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 1.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -15 0.99 -15 -5.21 -7.40 -5.14 1.07 1.45 -3.07 -59
Invested Capital Turnover		 -0.35 -0.43 -0.53 -0.30 -1.29 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 16 -16 10 -2.19 2.25 6.21 0.38 -4.52 -56
Enterprise Value (EV)		 0.00 103 52 91 51 84 377 269 69 140
Market Capitalization		 0.00 97 34 71 42 92 380 276 58 126
Book Value per Share		 ($5.56) ($0.23) ($1.36) ($0.35) ($0.57) $0.02 $0.03 $0.04 ($0.06) ($3.09)
Tangible Book Value per Share		 ($5.56) ($0.23) ($1.36) ($0.35) ($0.57) $0.02 $0.03 $0.04 ($0.06) ($3.09)
Total Capital		 -5.59 3.56 -12 -3.49 0.62 7.39 16 20 21 -44
Total Debt		 22 8.73 18 17 11 4.57 12 11 36 29
Total Long-Term Debt		 6.14 2.55 13 3.55 0.05 0.90 11 0.00 0.00 0.00
Net Debt		 13 6.38 15 16 3.37 -7.97 -3.54 -7.29 11 14
Capital Expenditures (CapEx)		 8.80 1.10 0.29 2.78 0.44 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -11 -23 -17 -3.47 -6.82 1.18 1.31 -3.59 -0.63
Debt-free Net Working Capital (DFNWC)		 -6.06 -8.58 -20 -15 4.55 5.72 16 19 20 14
Net Working Capital (NWC)		 -22 -15 -25 -29 -6.79 2.06 15 7.79 -16 -15
Net Nonoperating Expense (NNE)		 16 17 14 9.34 9.11 9.45 17 22 22 25
Net Nonoperating Obligations (NNO)		 13 6.16 15 16 3.37 -7.97 -3.54 -7.29 11 14
Total Depreciation and Amortization (D&A)		 1.82 2.39 2.69 3.05 3.36 0.55 0.26 0.20 0.04 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 -289.86% -366.97% -603.76% -540.56% -42.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -116.06% -288.03% -520.18% -484.94% 55.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 -419.17% -495.32% -651.53% -930.82% -83.34% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($868.80) ($587.20) ($267.20) ($195.20) ($39.60) ($13.40) ($7.00) ($6.20) ($4.80) ($4.06)
Adjusted Weighted Average Basic Shares Outstanding		 60.96K 147.37K 150.14K 246.61K 1.51M 6.36M 7.63M 10.60M 12.51M 18.55M
Adjusted Diluted Earnings per Share		 ($868.80) ($587.20) ($288.00) ($195.20) ($39.60) ($13.40) ($7.00) ($6.20) ($4.80) ($4.06)
Adjusted Weighted Average Diluted Shares Outstanding		 60.96K 147.37K 150.26K 246.61K 1.51M 6.36M 7.63M 10.60M 12.51M 18.55M
Adjusted Basic & Diluted Earnings per Share		 ($868.80) ($587.20) $0.00 $0.00 ($39.60) ($13.40) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.96K 107.58K 159.57K 531.82K 909.59K 3.63M 11.21M 11.41M 13.01M 24.91M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -36 -25 -21 -18 -25 -36 -44 -37 -50
Normalized NOPAT Margin		 -624.49% -1,206.31% -658.95% -672.08% -215.07% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -936.15% -1,785.46% -1,006.10% -1,092.78% -465.68% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -20.27 -27.73 -5.82 -5.56 -8.31 -9.54 -55.74 -25.27 -18.28 -0.87
NOPAT to Interest Expense		 -14.19 -19.41 -4.46 -4.03 -6.24 -7.06 -38.68 -17.57 -11.96 -1.23
EBIT Less CapEx to Interest Expense		 -24.10 -28.32 -5.87 -6.10 -8.42 -9.54 -55.74 -25.27 -18.28 -0.87
NOPAT Less CapEx to Interest Expense		 -18.02 -20.00 -4.52 -4.58 -6.34 -7.06 -38.68 -17.57 -11.96 -1.23
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Oncobiologics

This table displays calculated financial ratios and metrics derived from Oncobiologics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 260,245,017.00 260,245,017.00 260,257,517.00 23,405,637.00 - - 32,017,179.00 33,568,023.00 44,419,529.00 83,067,190.00 120,863,252.00
DEI Adjusted Shares Outstanding		 13,012,251.00 13,012,251.00 13,012,876.00 23,405,637.00 - - 32,017,179.00 33,568,023.00 44,419,529.00 83,067,190.00 120,863,252.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.00 -0.86 -8.78 1.90 - - -1.45 -0.60 -0.52 -0.05 -0.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -99.42%
EBITDA Growth		 4.65% 27.52% -1,031.14% 309.44% 141.39% 253.34% 39.94% -145.46% -232.19% 89.92% 5.53%
EBIT Growth		 4.92% 27.39% -1,029.73% 309.19% 141.14% 252.71% 39.93% -145.55% -232.59% 89.86% 5.60%
NOPAT Growth		 10.93% 34.20% -176.98% -54.05% -162.32% -109.31% 34.57% 43.65% 56.32% -13.20% 31.36%
Net Income Growth		 9.44% 40.10% -1,617.52% 314.80% 143.81% 255.46% 59.44% -145.38% -232.69% 90.39% -0.83%
EPS Growth		 9.44% 40.10% -1,440.38% 44.72% 129.81% 183.72% 81.27% 38.20% -152.78% 96.67% 72.73%
Operating Cash Flow Growth		 -24.30% -46.41% -137.44% -47.64% -33.28% 15.84% 13.93% 39.01% -36.21% 52.80% -76.54%
Free Cash Flow Firm Growth		 58.73% -165.06% 3,960.45% 1,693.85% 893.26% 185.35% -213.48% -239.95% -553.63% 94.82% 105.26%
Invested Capital Growth		 -311.93% 118.74% -6,361.29% -1,490.06% -1,828.51% -2,573.44% 94.47% 85.42% 57.23% -34.81% -97.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 110.55% -93.17%
EBITDA Q/Q Growth		 36.93% 14.58% -579.34% 157.23% -88.43% 216.47% -366.06% 56.68% 0.00% 79.72% -306.07%
EBIT Q/Q Growth		 36.91% 14.44% -577.90% 157.17% -88.48% 217.61% -366.67% 56.65% 0.00% 79.61% -303.73%
NOPAT Q/Q Growth		 31.32% 17.14% -83.47% -47.55% -16.94% 33.89% 59.86% -27.09% 0.00% -4.03% 22.93%
Net Income Q/Q Growth		 37.17% 13.95% -922.42% 138.86% -87.18% 205.34% -366.76% 56.53% 0.00% 80.69% -356.30%
EPS Q/Q Growth		 37.17% 13.95% -831.40% 88.89% 134.83% 132.26% -308.33% 63.33% 0.00% 86.84% -200.00%
Operating Cash Flow Q/Q Growth		 3.59% -2.28% -47.85% -1.27% 12.97% 35.42% -51.21% 28.24% 0.00% 47.60% -168.40%
Free Cash Flow Firm Q/Q Growth		 -13.18% -230.15% 980.81% -51.57% -43.67% -64.48% -2,690.18% 40.28% 0.00% 70.44% 160.62%
Invested Capital Q/Q Growth		 41.82% 134.09% -13,225.35% 38.92% 29.43% 56.28% 70.68% -61.19% 0.00% 7.56% -135.90%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 70.78% 0.00% -17.18% -95.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,331.47% 0.00% -3,659.12% -217,648.59%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,046.20% 0.00% -11,006.82% -124,255.28%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,333.42% 0.00% -3,682.99% -217,807.10%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,338.75% 0.00% -3,494.28% -233,554.85%
Tax Burden Percent		 100.00% 0.00% 100.00% 100.00% 100.00% 0.00% 100.01% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.76% 0.00% 148.28% 100.79% 104.11% 0.00% 100.12% 100.40% 100.17% 94.88% 107.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2,069.13% 1,199.76% 257.19% 210.93% 172.24% 125.44% -25.34% 71.88% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% -3,825.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.78% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -58.01% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 2,069.13% 1,199.76% 257.19% 210.93% 172.24% 125.44% -25.34% 71.88% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 211.55% 118.55% 0.00% 0.00% 93.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.72 -7.23 -13 -20 -23 -15 -8.67 -11 -9.44 -9.82 -7.57
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -732.34% 0.00% -7,704.78% -86,978.69%
Net Nonoperating Expense Percent (NNEP)		 209.37% 195.47% -1,273.59% 161,683.96% -226.88% -130.60% 348.67% 74.09% 52.53% -24.60% 228.24%
Return On Investment Capital (ROIC_SIMPLE)		 -41.31% -59.23% 14.81% 38.18% 52.43% 77.38% -1,489.38% 400.48% 499.55% 484.70% 72.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.22% 0.00% 117.18% 195.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 643.02% 0.00% 7,458.14% 86,791.32%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 473.97% 0.00% 3,531.51% 37,368.95%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,116.98% 0.00% 10,989.65% 124,160.28%
Earnings before Interest and Taxes (EBIT)		 -13 -11 -77 44 5.47 17 -46 -20 -23 -4.69 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -11 -77 44 5.50 17 -46 -20 -23 -4.66 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 35.68 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 1.85 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.07% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 122.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 52.25 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 2.65 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 2.67 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 1.63 4.82 23.39 0.00 0.00 0.00 0.00 13.55 14.97
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.46 -1.50 -0.33 -0.39 -0.40 -0.61 -1.02 -0.93 -0.95 -0.93 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 -0.65 -0.55 0.00 -0.38 0.00
Financial Leverage		 -0.72 -0.47 0.13 0.00 -0.29 -0.67 -0.13 -0.20 -0.58 -0.71 -0.23
Leverage Ratio		 -10.67 -9.83 -0.91 -1.03 -0.70 -0.52 -0.47 -0.57 -0.40 -0.67 -1.02
Compound Leverage Factor		 -10.43 0.00 -1.35 -1.03 -0.73 0.00 -0.47 -0.58 -0.40 -0.63 -1.09
Debt to Total Capital		 168.38% 299.53% -50.00% -63.29% -67.47% -157.29% 5,673.98% -1,251.01% -1,940.23% -1,331.30% 0.00%
Short-Term Debt to Total Capital		 168.38% 299.53% -50.00% -63.29% -67.47% -157.29% 2,060.46% -508.59% -1,940.23% -782.17% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,613.53% -742.43% 0.00% -549.12% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -68.38% -199.53% 150.00% 163.29% 167.47% 257.29% -5,573.98% 1,351.01% 2,040.23% 1,431.30% 100.00%
Debt to EBITDA		 -0.63 -0.70 -0.36 -0.56 -0.83 -4.60 1.37 -0.86 0.00 0.00 0.00
Net Debt to EBITDA		 -0.20 -0.48 0.03 0.01 -0.39 -3.65 1.03 -0.62 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.87 -0.51 0.00 0.00 0.00
Debt to NOPAT		 -0.96 -1.09 -1.07 -0.76 -0.59 -0.53 -0.43 -0.68 0.00 0.00 0.00
Net Debt to NOPAT		 -0.31 -0.76 0.08 0.01 -0.28 -0.42 -0.33 -0.49 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.28 -0.40 0.00 0.00 0.00
Altman Z-Score		 -21.49 -32.74 -17.82 -12.36 -25.65 -41.80 -50.00 -39.95 -53.79 -41.99 -34.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.66 0.44 1.07 1.07 0.64 0.32 0.72 0.67 0.35 0.54 0.81
Quick Ratio		 0.50 0.23 0.87 0.75 0.35 0.12 0.30 0.34 0.18 0.27 0.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.20 -14 122 59 33 12 -139 -83 -24 -7.17 4.35
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -15.54 0.00 3.28 0.00 127.32 0.00 -7,489.07 -1,676.81 0.00 0.00 3.27
Operating Cash Flow to Interest Expense		 -47.17 0.00 -0.52 0.00 -64.91 0.00 -896.32 -241.15 0.00 0.00 -15.81
Operating Cash Flow Less CapEx to Interest Expense		 -47.17 0.00 -0.52 0.00 -64.91 0.00 -896.32 -241.15 0.00 0.00 -15.81
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6,562.23 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6,562.23 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.07 1.05 -137 -84 -59 -26 -7.60 -12 -11 -10 -24
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.52 6.64 -135 -79 -56 -27 130 72 15 -2.65 -12
Enterprise Value (EV)		 69 128 152 172 140 71 64 79 98 36 178
Market Capitalization		 58 103 155 173 126 47 39 54 70 17 192
Book Value per Share		 ($0.06) ($1.87) ($0.52) ($3.57) ($3.09) ($2.02) ($1.01) ($1.11) ($0.64) ($0.35) ($0.09)
Tangible Book Value per Share		 ($0.06) ($1.87) ($0.52) ($3.57) ($3.09) ($2.02) ($1.01) ($1.11) ($0.64) ($0.35) ($0.09)
Total Capital		 21 12 -89 -51 -44 -20 0.58 -2.75 -1.89 -2.03 -10
Total Debt		 36 37 45 32 29 31 33 34 37 27 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 21 20 0.00 11 0.00
Net Debt		 11 25 -3.25 -0.30 14 24 25 25 27 19 -14
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.59 0.61 1.22 3.47 -0.63 -7.53 -2.57 -5.29 -3.91 -9.88 -17
Debt-free Net Working Capital (DFNWC)		 20 11 48 35 14 -1.83 4.98 3.61 4.77 -2.13 -5.51
Net Working Capital (NWC)		 -16 -26 3.71 3.06 -15 -33 -7.02 -10 -32 -18 -5.51
Net Nonoperating Expense (NNE)		 4.27 3.95 101 -64 -29 -33 38 9.13 14 -5.37 13
Net Nonoperating Obligations (NNO)		 11 25 -3.25 -0.30 14 24 25 25 27 19 -14
Total Depreciation and Amortization (D&A)		 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -351.65% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 239.64% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -690.40% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($20.80) ($0.80) ($8.01) $1.91 $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05) ($0.15)
Adjusted Weighted Average Basic Shares Outstanding		 625.44K 13.01M 14.27M 23.23M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M 136.74M
Adjusted Diluted Earnings per Share		 ($20.80) ($0.80) ($8.01) ($0.89) $0.31 $0.72 ($1.50) ($0.55) ($0.38) ($0.05) ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding		 625.44K 13.01M 14.27M 25.48M 18.55M 24.23M 30.87M 36.96M 60.21M 81.84M 136.74M
Adjusted Basic & Diluted Earnings per Share		 ($20.80) $0.00 $0.00 $0.00 $0.31 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.01M 13.01M 23.41M 23.66M 24.91M 32.02M 33.57M 44.42M 83.07M 120.86M 243.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.72 -7.23 -13 -14 -16 -15 -8.67 -11 -9.44 -9.82 -7.57
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -732.34% 0.00% -7,704.78% -86,978.69%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,338.75% 0.00% -3,494.28% -233,554.85%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -49.19 0.00 -2.07 0.00 20.90 0.00 -2,502.40 -406.72 0.00 0.00 -14.26
NOPAT to Interest Expense		 -32.29 0.00 -0.36 0.00 -87.45 0.00 -468.82 -223.38 0.00 0.00 -5.69
EBIT Less CapEx to Interest Expense		 -49.19 0.00 -2.07 0.00 20.90 0.00 -2,502.40 -406.72 0.00 0.00 -14.26
NOPAT Less CapEx to Interest Expense		 -32.29 0.00 -0.36 0.00 -87.45 0.00 -468.82 -223.38 0.00 0.00 -5.69
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Financial statement trends for Outlook Therapeutics (NASDAQ:OTLK) show a company still in a pre-profitability phase, with recurring operating losses, limited revenue and continued reliance on external financing. The data provided identifies the company as Outlook Therapeutics, although the prompt refers to Oncobiologics.

  • Cash increased sequentially: Cash and equivalents rose to $11.2 million at June 30, 2026, from $7.7 million at March 31, 2026. The increase was primarily supported by $26.6 million of net financing cash flow, including $25.2 million from common-equity issuance.
  • Liabilities declined from the prior quarter: Total liabilities fell to $36.6 million from $50.9 million, while current liabilities declined to $28.7 million from $38.9 million. Reported short-term and long-term debt were both zero at June 30, 2026, compared with $26.0 million of combined debt in the prior quarter.
  • Operating expenses have generally moderated: Third-quarter selling, general and administrative expense was $7.5 million and research and development expense was $3.3 million, down from $9.5 million and $4.5 million, respectively, in the second quarter.
  • Losses improved compared with early 2025: The $20.3 million third-quarter 2026 net loss was smaller than the $46.4 million loss reported for the second quarter of 2025, although losses remain substantial.
  • Cash remains heavily dependent on financing: The company reported a $3.5 million increase in cash during the quarter despite using $21.0 million in operating activities and $2.1 million in investing activities. This indicates that recent liquidity has been sustained through capital-market activity rather than internally generated cash.
  • Financial comparisons require caution: Several historical income statements are marked as restated or calculated, and some prior-period figures include unusually large other gains or expenses. These items make year-over-year earnings comparisons less reliable.
  • Revenue has collapsed: Third-quarter 2026 revenue was only $8,700, down from $127,439 in the second quarter and $1.5 million in the year-ago quarter. Revenue was insufficient to cover the $17,000 cost of revenue, producing a gross loss of $8,265.
  • Net losses remain severe: The company posted a $20.3 million net loss, or $0.15 per basic and diluted share, in the third quarter. The loss widened sharply from $4.5 million in the prior quarter and was broadly similar to the $20.2 million loss in the year-ago quarter.
  • Operating cash burn accelerated: Net cash used in operating activities increased to $21.0 million in the third quarter from $7.8 million in the second quarter and $11.9 million a year earlier. At the latest quarterly burn rate, the $11.2 million cash balance alone would provide limited runway without additional financing or a major reduction in spending.
  • Balance-sheet solvency remains weak and dilution is significant: Shareholders’ equity was negative $10.4 million at June 30, 2026, and current assets of $23.2 million were below current liabilities of $28.7 million. Weighted-average basic shares outstanding increased to 136.7 million in the third quarter from 81.8 million in the second quarter, reflecting substantial dilution from equity financing.

Overall, the statements show some improvement in reported debt and quarterly operating expenses, but these gains are outweighed by minimal revenue, persistent losses, negative equity and substantial cash consumption. Investors should closely monitor commercial revenue growth, operating cash flow and whether future funding comes from additional equity issuance, which could further dilute existing shareholders.

11/13/26 10:44 AM ETAI Generated. May Contain Errors.

Oncobiologics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Oncobiologics' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

Oncobiologics' net income appears to be on a downward trend, with a most recent value of -$75.37 million in 2024, falling from -$48.67 million in 2015. The previous period was -$58.98 million in 2023. View Oncobiologics' forecast to see where analysts expect Oncobiologics to go next.

Oncobiologics' total operating income in 2024 was -$71.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $71.70 million

Over the last 9 years, Oncobiologics' total revenue changed from $5.22 million in 2015 to $0.00 in 2024, a change of -100.0%.

In the past 10 quarters, Oncobiologics' cash and equivalents has ranged from $5.70 million in Q1 2025 to $47.23 million in Q2 2024, and is currently $11.24 million as of their latest financial filing in Q3 2026.

Oncobiologics had total debt of $29.44 million at the end of 2024, a 17.2% decrease from 2023, and a 34.1% increase since 2015.

Over the last 9 years, Oncobiologics' book value per share changed from -5.56 in 2015 to -3.09 in 2024, a change of 44.4%.


Related Companies

Financial statements for NASDAQ:OTLK last updated on 8/18/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel
This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...
Patriot Gold Group | Sponsoredtc pixel